AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8583024 — intervention group
Group type: COMPARATOR
Intervention: Image capture system linked to a computerised image programme
Number of subjects: 12
Study 2224950 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate 20 micrograms
Number of subjects: 176
Study 2224950 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate 40 micrograms
Number of subjects: 176
Study 2224950 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (during open-label period)
Number of subjects: 176
Study 2224950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 6965330 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective distal splenorenal shunt
Number of subjects: 0
Study 6965330 — intervention group
Group type: COMPARATOR
Intervention: End‐to‐side portacaval shunt
Number of subjects: 0
Study 6965330 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective distal splenorenal shunt and End‐to‐side portacaval shunt
Number of subjects: 0
Study 31634418 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Risk Score (GRS)
Number of subjects: 0
Study 31634418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pruning and Thresholding (P + T)
Number of subjects: 0
Study 31634418 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage Disequilibrium Prediction (LDpred)
Number of subjects: 0
Study 30703523 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (individual phone counseling and social marketing campaign)
Number of subjects: 352
Study 30703523 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 352
Study 28121172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation consisting of 12 weeks of physical exercise training and monthly psycho-educational consultations
Number of subjects: 147
Study 28121172 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study 25811287 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine
Number of subjects: 500
Study 25811287 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine
Number of subjects: 500
Study 23890493 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plates (VLP)
Number of subjects: 111
Study 23890493 — intervention group
Group type: COMPARATOR
Intervention: External fixation (EF)
Number of subjects: 111
Study 23890493 — intervention group
Group type: COMPARATOR
Intervention: Volar locking plates (VLP) and External fixation (EF)
Number of subjects: 111
Study 21980810 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 16
Study 21980810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 19671410 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu (XFZY) Capsule
Number of subjects: 90
Study 19671410 — intervention group
Group type: COMPARATOR
Intervention: Shengmai (SM) Capsule
Number of subjects: 90
Study 19671410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17077230 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased access to emergency contraceptive pills (two packages dispensed in advance with unlimited resupply at no charge)
Number of subjects: 1490
Study 17077230 — intervention group
Group type: COMPARATOR
Intervention: Standard access to emergency contraceptive pills (pills dispensed when needed at usual charges)
Number of subjects: 1490
Study 17077230 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased access to emergency contraceptive pills
Number of subjects: 1490
Study 17077230 — intervention group
Group type: COMPARATOR
Intervention: Standard access to emergency contraceptive pills
Number of subjects: 1490
Study 15582766 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by lay person
Number of subjects: 38
Study 15582766 — intervention group
Group type: COMPARATOR
Intervention: Training by health care professional
Number of subjects: 38
Study 11531217 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-supplemented TPN (2 g choline chloride added)
Number of subjects: 15
Study 11531217 — intervention group
Group type: COMPARATOR
Intervention: Usual TPN (placebo)
Number of subjects: 15
Study 9989314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral stress management program (CBSM)
Number of subjects: 34
Study 9989314 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 8091249 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin i.v. once a day
Number of subjects: 96
Study 8091249 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin i.m. once a day
Number of subjects: 96
Study 8091249 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin i.v. every 8 hours
Number of subjects: 96
Study 3069751 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tablets of 100 mg ibopamine (SIMES formulations)
Number of subjects: 30
Study 3069751 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tablets of 100 mg ibopamine (UK formulation)
Number of subjects: 30
Study 3069751 — intervention group
Group type: EXPERIMENTAL
Intervention: One tablet of 200 mg ibopamine (US-Tiltab formulation)
Number of subjects: 30
Study 3069751 — intervention group
Group type: EXPERIMENTAL
Intervention: One tablet of 200 mg ibopamine (US-Tiltab formulation) on a 4th occasion
Number of subjects: 30
Study 31911667 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (DMAb)
Number of subjects: 0
Study 31911667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31911667 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonates or calcium and vitamin D
Number of subjects: 0
Study 29465052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope (FOB)
Number of subjects: 80
Study 29465052 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscope (DLS)
Number of subjects: 80
Study 27353617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy surveillance performance (referrals of pregnant women)
Number of subjects: 342
Study 27353617 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and hygiene education performance (lesson delivery)
Number of subjects: 342
Study 27353617 — intervention group
Group type: EXPERIMENTAL
Intervention: Job satisfaction and motivation measures
Number of subjects: 342
Study 24584382 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimebutine 100mg twice daily
Number of subjects: 140
Study 24584382 — intervention group
Group type: COMPARATOR
Intervention: Mebeverine 135mg twice daily
Number of subjects: 140
Study 23228348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 37
Study 23228348 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (IFX)
Number of subjects: 37
Study 21422302 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine plus bupivacaine plus clonidine
Number of subjects: 120
Study 21422302 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine plus bupivacaine
Number of subjects: 120
Study 21422302 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 120
Study 18450862 — intervention group
Group type: EXPERIMENTAL
Intervention: European Bladder Dysfunction Study treatment
Number of subjects: 202
Study 16181604 — intervention group
Group type: EXPERIMENTAL
Intervention: Matte objects with illumination from different directions
Number of subjects: 6
Study 16181604 — intervention group
Group type: COMPARATOR
Intervention: Glossy objects with illumination from different directions
Number of subjects: 6
Study 15071263 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 18
Study 15071263 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospital admission strategy
Number of subjects: 18
Study 11068971 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional treatment foster care
Number of subjects: 0
Study 11068971 — intervention group
Group type: COMPARATOR
Intervention: Services-as-usual group care
Number of subjects: 0
Study 8718542 — intervention group
Group type: EXPERIMENTAL
Intervention: Estriol (E3) 2 mg/day + Calcium lactate (Ca) 2 g/day (Group-E3 + Ca)
Number of subjects: 25
Study 8718542 — intervention group
Group type: COMPARATOR
Intervention: Calcium lactate (Ca) 2 g/day (Group-Ca)
Number of subjects: 25
Study 1400926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination of oestradiol valerate (2 mg, days 1-28) and levonorgestrel (75 micrograms, days 17-28)
Number of subjects: 59
Study 1400926 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combination of oestradiol valerate (2 mg, days 1-28) and cyproterone acetate (1 mg, days 1-28)
Number of subjects: 59
Study 1400926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 2935765 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% etidocaine 5 mL dropped on each fallopian tube before tubal banding
Number of subjects: 51
Study 2935765 — intervention group
Group type: COMPARATOR
Intervention: No topical anesthetic agent
Number of subjects: 51
Study 2935765 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% etidocaine 5 mL
Number of subjects: 51
Study 31567602 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 52
Study 28404769 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 60
Study 26216195 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (32.2 g pre- and post-rehabilitation for two weeks)
Number of subjects: 38
Study 26216195 — intervention group
Group type: COMPARATOR
Intervention: Control group (no whey protein)
Number of subjects: 38
Study 24531027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube shunt (350 mm² Baerveldt glaucoma implant)
Number of subjects: 212
Study 24531027 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (0.4 mg/mL for 4 minutes)
Number of subjects: 212
Study 24531027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube shunt
Number of subjects: 212
Study 24531027 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 212
Study 22796902 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich dark chocolate (DC) 20 g containing 500 mg polyphenols
Number of subjects: 42
Study 22796902 — intervention group
Group type: COMPARATOR
Intervention: Placebo DC with negligible polyphenol-content
Number of subjects: 42
Study 22796902 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich dark chocolate (DC)
Number of subjects: 42
Study 20028945 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention for 1 year
Number of subjects: 58
Study 17901959 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary calcium scores (CCS) by electron beam computed tomography (Agatston score)
Number of subjects: 304
Study 17901959 — intervention group
Group type: COMPARATOR
Intervention: Exercise testing
Number of subjects: 304
Study 19372312 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat blood gas management
Number of subjects: 40
Study 19372312 — intervention group
Group type: COMPARATOR
Intervention: alpha-stat blood gas management
Number of subjects: 40
Study 15022053 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-hold (BH) phase-contrast technique
Number of subjects: 32
Study 15022053 — intervention group
Group type: COMPARATOR
Intervention: Non breath-hold (NBH) cine phase-contrast technique
Number of subjects: 32
Study 11281233 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mmol/day salt intake
Number of subjects: 55
Study 11281233 — intervention group
Group type: COMPARATOR
Intervention: 150 mmol/day salt intake
Number of subjects: 55
Study 11281233 — intervention group
Group type: EXPERIMENTAL
Intervention: Both salt intake levels
Number of subjects: 55
Study 9388791 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated printed feedback (Experimental group)
Number of subjects: 679
Study 9388791 — intervention group
Group type: COMPARATOR
Intervention: Control group (no printed feedback)
Number of subjects: 679
Study 8187369 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 139
Study 8187369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 8187369 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 139
Study 3250183 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) oral tablets
Number of subjects: 69
Study 3250183 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 69
Study 30658649 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg every 8 weeks (first three doses every 4 weeks) subcutaneously
Number of subjects: 0
Study 28254084 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS reminders for medications
Number of subjects: 1198
Study 28254084 — intervention group
Group type: COMPARATOR
Intervention: No SMS reminders (Control)
Number of subjects: 1198
Study 26172565 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacement shakes
Number of subjects: 5
Study 26172565 — intervention group
Group type: COMPARATOR
Intervention: Behavioral weight management program
Number of subjects: 5
Study 23664683 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 0
Study 23664683 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain perception
Number of subjects: 0
Study 19691834 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation (2224 mg EPA + 2208 mg DHA for 6 weeks)
Number of subjects: 14
Study 19691834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19691834 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA supplementation
Number of subjects: 14
Study 17088909 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 753
Study 17088909 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 753
Study 17088909 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP2A amplification
Number of subjects: 753
Study 17088909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative anthracycline dose
Number of subjects: 753
Study 17088909 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminal-like tumours
Number of subjects: 753
Study 14702491 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder/recall for influenza vaccination
Number of subjects: 2007
Study 14702491 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminder/recall)
Number of subjects: 2007
Study 11721215 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine + Vit. C
Number of subjects: 64
Study 11721215 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorpheniramine + Vit. C
Number of subjects: 64
Study 11721215 — intervention group
Group type: COMPARATOR
Intervention: Vit. C alone
Number of subjects: 64
Study 9131280 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of diabetic retinopathy
Number of subjects: 12
Study 7697674 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.25 mg/kg)
Number of subjects: 18
Study 7697674 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.15 mg/kg)
Number of subjects: 18
Study 3652753 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration (drinking one glass of fluid every waking hour after supper and upon waking the next morning)
Number of subjects: 12
Study 3652753 — intervention group
Group type: COMPARATOR
Intervention: Dry (drinking no fluid after supper and upon waking the next morning)
Number of subjects: 12
Study 3652753 — intervention group
Group type: COMPARATOR
Intervention: Ad lib (drinking fluid ad libitum)
Number of subjects: 12
Study 29973190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (14 sessions of 60 min during an academic year)
Number of subjects: 172
Study 29973190 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 172
Study 26874511 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of valsartan (low-dose group)
Number of subjects: 43
Study 26874511 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of valsartan (regular-dose group)
Number of subjects: 43
Study 25130503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster immunotherapy with high polymerized allergen extract of grass/rye pollen mixture
Number of subjects: 121
Study 25130503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 23350192 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaxol
Number of subjects: 0
Study 19967558 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg daily)
Number of subjects: 67
Study 19967558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 18696285 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine adhesive patch (1.0mg, 1.5mg, or 2.0mg per week for 4 weeks)
Number of subjects: 437
Study 18696285 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine adhesive patch
Number of subjects: 437
Study 18696285 — intervention group
Group type: COMPARATOR
Intervention: Placebo adhesive patch
Number of subjects: 437
Study 16159626 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus illnesses during infancy
Number of subjects: 285
Study 16159626 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheezing during rhinovirus seasons
Number of subjects: 285
Study 11837055 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricting bending activities in the early morning
Number of subjects: 60
Study 11837055 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 60
Study 9613269 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.2 mg.kg‐1
Number of subjects: 60
Study 8598261 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) at low dosage
Number of subjects: 225
Study 8598261 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 225
Study 2750570 — intervention group
Group type: EXPERIMENTAL
Intervention: Description of a fellow student as a smoker
Number of subjects: 0
Study 2750570 — intervention group
Group type: COMPARATOR
Intervention: Description of a fellow student without the smoking information
Number of subjects: 0
Study 1058422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment containing estrone alone
Number of subjects: 61
Study 1058422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment of estrone and progesterone
Number of subjects: 61
Study 1058422 — intervention group
Group type: COMPARATOR
Intervention: Placebo base ointment
Number of subjects: 61
Study 31806426 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 1629
Study 30390361 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 2964
Study 30390361 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change among high-weight participants
Number of subjects: 2964
Study 30390361 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss >5%
Number of subjects: 2964
Study 30390361 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss 0-<=5%
Number of subjects: 2964
Study 30390361 — intervention group
Group type: COMPARATOR
Intervention: Weight gain 0-<5% (reference group)
Number of subjects: 2964
Study 30390361 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain >5%
Number of subjects: 2964
Study 27320184 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) prevalence in participants with prior CVD
Number of subjects: 9340
Study 27320184 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical prevalence of CKD
Number of subjects: 9340
Study 27320184 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with increased CKD prevalence
Number of subjects: 9340
Study 27320184 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with decreased CKD prevalence
Number of subjects: 9340
Study 23804562 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus physical activity (D-PA)
Number of subjects: 116
Study 23804562 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (DO)
Number of subjects: 116
Study 22425411 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 56
Study 22425411 — intervention group
Group type: COMPARATOR
Intervention: Drug Counseling (DC)
Number of subjects: 56
Study 20074324 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Number of subjects: 0
Study 20074324 — intervention group
Group type: COMPARATOR
Intervention: Resurfacing Arthroplasty
Number of subjects: 0
Study 18751444 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (PTX) 80 mg/m2 weekly
Number of subjects: 30
Study 18751444 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 12.5 mg/m2 every two weeks
Number of subjects: 30
Study 18751444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PTX and PLD
Number of subjects: 30
Study 15721116 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) implantation
Number of subjects: 137
Study 12873918 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 micro g/kg IV fentanyl 10 min before discontinuation of anesthetic
Number of subjects: 32
Study 12873918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 32
Study 11783029 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin solution (injection group)
Number of subjects: 121
Study 11783029 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin powder (control group)
Number of subjects: 121
Study 11783029 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (study and control)
Number of subjects: 121
Study 9196144 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM plus CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2 every 21 days for eight cycles)
Number of subjects: 705
Study 1604252 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 47
Study 1604252 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 47
Study 3886325 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin stapling technique
Number of subjects: 50
Study 3886325 — intervention group
Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 50